China cardiovascular drugs market set to grow to 45 billion renminbi by 2018

13 June 2014
china-big

A new report titled Research on China Cardiovascular Drugs Industry 2014-2018, says that, in the next 10 years, there is a potential for the growth in cardiovascular diseases treatment field.

It is predicted that the growth rate will be of more than 20% from 2014 to 2018. This report, added to the offering of MarketReportsChina.com, estimates that the sales of cardiovascular drugs in China in 2014 will reach about 22 billion renminbi ($3.52 billion), and the figure will be 45 billion renminbi by 2018.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical